1、教育经历
(1) 2018/09-2021/06, 中国药科大学, 药学院, 博士
(2) 2015/09-2018/06, 中国药科大学, 药学院, 硕士
(3) 2011/09-2015/06, 中国药科大学, 药学院, 学士
2、工作经历
(1) 2021/07- 至今, 中国药科大学,药学院,博士后
3、学术荣誉
2022/06,江苏省卓越博士后
智能药物递送系统与心血管疾病治疗
1、科研项目
(1) 国家自然科学基金委员会, 面上项目, 82073782, 基于“膜-锚定”策略的PDK与TGF-β1抑制剂的联合递送及其抗肺血管重构作用研究, 2021-01-01至2024-12-31, 55万元, 在研, 参与
(2) 国家自然科学基金委员会, 面上项目, 81872823, 基于“药物-递送-药物”策略的黄芩素-pDNA靶向纳米系统的构建及其抗肺动脉高压研究, 2019-01-01至2022-12-31, 57万元, 在研, 参与
(3) 国家自然科学基金委员会, 青年科学基金项目, 81603051, 纤维激活蛋白-α(FAP-α)响应的PEG化修饰提高透明质酸纳米粒递药效率机制的研究, 2017-01-01至2019-12-31, 17.3万元, 结题, 参与
2、学术获奖
(1)2020,江苏省大健康产业创新成果最佳风采奖,排名第一
1.Chao Teng; Bingbing Li; Chenshi Lin; Xuyang Xing; Feifei Huang; Yi Yang; Yi Li; Helena S. Azevedo; Wei He*. Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension[J]. Journal of Controlled Release, 2022, 341: 591-604. (IF: 11.467)
2.Qingqing Xiao, Makhloufi Zoulikha, Min Qiu, Chao Teng, Chenshi Lin, Xiaotong Li, Marwa A. Sallam, Qiaobing Xu*, WeiHe*. The effects of protein corona on in vivo fate of nanocarriers[J]. Advanced Drug Delivery Reviews, 2022: 114356. (IF: 17.873)
3.Yi Li, Chao Teng, Helena S. Azevedo, Lifang Yin*, Wei He*. Cocrystallization-like strategy for the codelivery of hydrophobic and hydrophilic drugs in a single carrier material formulation[J]. Chinese Chemical Letters, 2021, 32(10): 3071-3075. (共一,IF: 6.779)
4.Chao Teng; Chenshi Lin; Feifei Huang; Xuyang Xing; Shenyu Chen; Ling Ye; Helena S. Azeved o; Chenjie Xu; Zhengfeng Wu; Zhongjian Chen; Wei He*. Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treat inflammatory disease[J]. Acta Pharmaceutica Sinica B, 2020, 10(8): 1521-1533. (IF: 11.413)
5.Chao Teng; Beiyuan Zhang; Zhongyue Yuan; Zheng Kuang; Zhuodong Chai; Lianjie Ren; Chao Qi n; Lei Yang; Xiaopeng Han*; Lifang Yin*. Fibroblast activation protein-α-adaptive micelles deliver anti-cancer drugs and reprogram stroma fibrosis[J]. Nanoscale, 2020, 12(46): 23756-23767. (IF: 6.895)
6.Chao Teng; Zhuodong Chai; Zhongyue Yuan; Lianjie Ren; Chenshi Lin; Zhen Yan; Wei He; Chao Qin; Lei Yang; Xiaopeng Han*; Lifang Yin*. Desirable PEGylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and CD44 receptor-mediated tumor targeting[J]. Nanomedicine: Nanotechnology, Biology and Medicine, 2020, 24: 102105. (IF: 6.458)
7.Jianming Zhang, Chao Teng, Caolong Li, Wei He*. Deliver anti-inflammatory drug baicalein to macrophages by using a crystallization strategy[J]. Frontiers in Chemistry, 2020, 8: 787. (共一,IF: 3.693)
8.Zhuodong Chai, ChaoTeng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han*, Lifang Yin *. Doxorubicin delivered by redox-responsive Hyaluronic Acid–Ibuprofen prodrug micelles for treatment of metastatic breast cancer[J]. Carbohydrate polymers, 2020, 245: 116527. (IF: 7.182)
9.Xiaofei Xin, Chao Teng, Xiaoqing Du, Yaiqi Lv, Qingqing Xiao, Yubing Wu, Wei He*, and Lifang Yin*. Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route[J]. Theranostics, 2018, 8(13): 3474. (IF: 8.063)